Perspective Therapeutics (NYSE:CATX) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research report released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Perspective Therapeutics’ Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.19) EPS.

Several other equities research analysts also recently weighed in on the company. Scotiabank initiated coverage on Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $24.00 to $5.00 in a report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Trading Down 1.1 %

Perspective Therapeutics stock opened at $2.59 on Thursday. The company’s 50 day moving average is $3.14 and its two-hundred day moving average is $7.26. Perspective Therapeutics has a 52-week low of $2.32 and a 52-week high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the period. Millennium Management LLC purchased a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $4,132,000. State Street Corp boosted its stake in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after buying an additional 1,192,812 shares during the period. Octagon Capital Advisors LP grew its holdings in shares of Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after buying an additional 882,528 shares during the last quarter. Finally, Affinity Asset Advisors LLC increased its position in Perspective Therapeutics by 160.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after acquiring an additional 800,000 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.